Personalized cancer therapy coming of age: Clinical highlights in 2009 and future directions

Personalized Medicine

Volumn 7, Issue 2, 2010, Pages 121-124

  Ma, Brigette By ^a,b,c,d   Loong, Herbert ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b State Key Laboratory in Oncology   (Hong Kong)

^c Hong Kong Cancer Institute   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB;

CANCER RESEARCH; CANCER THERAPY; COLORECTAL CANCER; DNA METHYLATION; DRUG SCREENING; EDITORIAL; HEALTH SERVICE; HUMAN; LUNG CANCER; ONCOLOGY; PRIORITY JOURNAL;

EID: 77949725711     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.11     Document Type: Editorial

References (31)

1. Kopetz S, Freitas D, Calabrich A et al.: Adjuvant chemotherapy for stage II colon cancer. Oncology (Williston Park) 22(3), 260-270 (2008).
2. Shepherd F, Rodrigues Pereira J, Ciuleanu T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
3. Mok T, Wu Y, Thongprasert S et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
4. Pirker R, Pereira JR, Szczesna A et al.: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet 373(9674), 1525-1531 (2009).
5. Piccart-Gebhart M, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
6. Slamon D, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
7. Geyer C, Forster J, Lindquist D et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
8. Cunningham D, Humblet Y, Siena S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
9. Jonker D, O'Callaghan C, Karapetis C et al.: Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040-2048 (2007).
10. Wolff A, Hammond M, Schwartz J et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007).
11. Chung K, Shia J, Kemeny N et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23(9), 1803-1810 (2005).
12. Fukuoka M, Yano S, Giaccone G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J. Clin. Oncol. 21(12), 2237-2246 (2003).
13. Giaccone G, Herbst R, Manegold C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004).
14. Herbst R, Giaccone G, Schiller J et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial - INTACT 2. J. Clin. Oncol. 22(5), 785-794 (2004).
15. Paez J, Janne P, Lee J et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
16. Shigematsu H, Lin L, Takahashi T et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97(5), 339-346 (2005).
17. Heinrich M, Corless C, Demetri G et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21(23), 4342-4349 (2003).
18. Fong P, Boss D, Yap T et al.: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123-134 (2009).
19. Linardou H, Dahabreh I, Kanaloupiti D et al.: Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9(10), 962-972 (2008).
20. Amado R, Wolf M, Peeters M et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
21. Van Cutsem E, Kohne C, Hitre E et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
22. Tol J, Koopman M, Cats A et al.: Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563-572 (2009).
23. Hecht J, Mitchell E, Chidiac T et al.: A randomized Phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672-680 (2009).
24. Hegi M, Diserens A, Gorlia T et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005).
25. Gorlia T, Van Den Bent M, Hegi M et al.: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial. Lancet Oncol. 9(1), 29-38 (2008).
26. Lo S, Mumby P, Norton J et al.: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J. Clin. Oncol. (2010) (Epub ahead of print).
27. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group: Recommendations from the EGAPP working group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet. Med. 11(1), 66-73, (2009).
28. Innocenti F, Kroetz Dl, Schuetz E et al.: Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 27(16), 2604-2614 (2009).
29. Hoskins J, Qu P, Ibrahim J, Mcleod H: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007).
30. Punglia R, Winer E, Weeks J: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J. Natl Cancer Inst. 100(9), 642-648 (2008).
31. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group: Recommendations from the EGAPP working group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet. Med. 11(1), 15-20 (2009).